All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke with Andrew Davies, University of Southampton, Southampton, UK. We asked, Can frontline treatment of DLBCL be improved by combining novel agents with R-CHOP?
Can frontline treatment of DLBCL be improved by combining novel agents with R-CHOP?
Davies begins by explaining how frontline therapies can be stratified according to biological risk factors and reviewing data on the potential benefit of augmented therapy in high-risk patients. Davies then discusses the impact of adding bortezomib to R-CHOP on overall and progression-free survival in patients with certain molecular subgroups of DLBCL. Finally, he reviews other novel therapies showing promise in combination with R-CHOP, including acalabrutinib and glofitamab.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
How to treat newly diagnosed DLBCL
The Lymphoma Hub Steering Committee discuss how the treatment of patients with DLBCL varies in different countries, with a focus on the current use of clinical pathology for the diagnosis of subtypes and how this...
Phase I study of CD20-TCB, a novel T-cell-engaging bispecific antibody, in R/R NHL
During the 25th Congress of the European Hematology Association (EHA), the Lymphoma Hub spoke to Michael Dickinson, Peter MacCallum Cancer Centre and The Royal...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox